About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Levosimendan for Veno-arterial ECMO Weaning

Levosimendan for Veno-arterial ECMO Weaning

NCT04323709·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hospices Civils de Lyon

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age ≥18 years
All consecutive patients admitted with VA-ECMO support for refractory cardiogenic shock
All consecutive patients admitted for lobectomy or wedge video-assisted thoracoscopy
Levosimendan administration was left to the discretion of the attending clinician

You may not be if

Age \< 18 years
VA-ECMO duration \< 48h
VA-ECMO for refractory cardiac arrest
Right heart or veno-venous ECMO
VA-ECMO for circulatory failure following lung transplant surgery.

The record

StatusCompleted

PhaseNo phase

Taking part200

StartedJan 2019

UpdatedMar 26, 2020

Conditions

Cardiogenic Shock Refractory Shock

Where1

Hôpital Louis Pradel
Bron, France